Home > Back to Category > Report Information

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System

NeuroInsights, LLC
May 18, 2007
369 Pages - SKU: NEI1560925

Abstract Table of Contents Search inside this report Related Reports

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is a market analysis and strategic investment guide of the global neurological disease and psychiatric illness markets. The report focuses on the more than 500 public and private companies translating advances in neuroscience into tomorrow's treatments. It provides insight and analysis of issues such as corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry. The report provides an in-depth look at fifteen brain and central nervous system disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, memory decline, obesity, pain, Parkinson's, psychiatric disorders, stroke and other brain-related illnesses.

1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications: 1-2: Global Pharmaceutical Sales by Indication, 2006; 1-3: Neurotechnology Industry Taxonomy; 1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity; 1-5: NASDAQ NeuroInsights Neurotech Index Performance vs. S&P500, and NASDAQ Biotechnology Index
2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020: 2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2011; 2-3: Neurotechnology Patent Approvals, US, 1985-2006; 2-4: Neuropharmaceutical Patent Approvals, US, 1985-2006; 2-5: Neurodevice Patent Approvals, US, 1985-2006; 2-6: Neurodiagnostic Patent Approvals, US, 1985-2006; 2-7: Selected US Foundations with a Significant focus on Brain Research and Education; 2-8: Most Generous Philanthropists for Medical and Brain Research; 2-9: Global Stem Cell Policy Map
3-1: Neuropharmaceutical Revenues by Indication (2006): 3-2: FDA Pharmaceutical Approval Process; 3-3: Big Pharma neuropharmaceutical revenues; 3-4: Neuropharmaceutical Partnering and Licensing Deals 2004-Q1 2007; 3-5: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism); 3-6: Worldwide revenues of leading anti-epileptics (2004-2006); 3-7: Clinical Trials for Epilepsy (company, compound, phase, mechanism); 3-8: Clinical Trials for Mild Cognitive impairment (company, compound, phase, mechanism); 3-9: Clinical Trials for Parkinson’s disease (company, compound, phase, mechanism); 3-10: Clinical Trials for sleep disorders (company, compound, phase, mechanism); 3-11: Clinical Trials for stroke Treatment (company, compound, phase, mechanism); 3-12: Number of People with Addiction and Impulse Control Disorders (WW and US); 3-13: Clinical Trials for addition and substance abuse (company, compound, phase, mechanism); 3-14: Clinical Trials for anxiety disorders (company, compound, phase, mechanism); 3-15: Clinical Trials for ADHD (company, compound, phase, mechanism); 3-16: Clinical Trials for Depressive disorders (company, compound, phase, mechanism); 3-17: Clinical Trials for Obesity Treatment (company, compound, phase, mechanism); 3-18: Clinical Trials for Schizophrenia and psychosis (company, compound, phase, mechanism); 3-19: Clinical Trials for Retinal disorders (company, compound, phase, mechanism); 3-20: Clinical Trials for Pain (company, compound, phase, mechanism)
4-1: FDA Classification and Approval Process for Medical Devices: 4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J; 4-3: Neurodevice Markets (Neuroprosthetic, Neuromodulation, Neurosurgical, Neurofeedback); 4-4: Neuromodulation Device Clinical Trials
5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics): 5-2: FDA Approval and Insurance Reimbursement of Diagnostics; 5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG); 5-4: Projected Number of Pharmacogenetic Tests by Indication 2003-2013; 5-5: Medical Divisions of Fortune 500 Dominate Neuroimaging Market; 5-6: Alzheimer’s Disease Neuroimaging Initiative; 5-7: Neuroinformatics Data Storage; 5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
6-1: Total US Venture Capital Investment, 1999-2006: 6-2: US Life Science Venture Capital Investment, 1999-2006; 6-3: US Neurotechnology Venture Capital Investment, 1999-2006; 6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2006; 6-5: Top Five Neurotechnology Venture Capital Financings, 2001-2006; 6-6: Top 12 Neurotech Venture Capital Firms with Investments
7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2007: 7-2: Selected Neurotech M&A Activity, 2004-Q1 2007; 7-3: Neurotech Index Companies 2007; 7-4: Neurotech Index Company Fundamentals; 7-5: Index Company Performance
8-1 Leading Neurotechnology Research Centers: 8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry; 8-3: UCSF; 8-4: UCLA; 8-5: Harvard University; 8-6: Stanford University; 8-7: MIT; 8-8: Columbia University; 8-9: Washington University; 8-10: University College London; 8-11: Karolinska Institute; 8-12: RIKEN Brain Science Institute
9-1 NeuroInsights’ Leading Neurotech Nexus Ratings: 9-2 Conclusions and Policy Recommendations
10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors): 10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description); 10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors); 10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description); 10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors); 10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System

Share this report

Other tasks

Research Assistance

Related Markets

Behavioral Health Reports

Free Alert Me service